selected publications
-
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
Cancer medicine.
2020
Academic Article
GET IT
Times cited: 12 - Clinical implications of drug-induced liver injury in early-phase oncology clinical trials. Cancer. 2020 Academic Article GET IT
-
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
The oncologist.
2020
Academic Article
GET IT
Times cited: 12 -
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020
Academic Article
GET IT
Times cited: 148 -
Characterization of on-target adverse events caused by TRK inhibitor therapy.
Annals of oncology : official journal of the European Society for Medical Oncology.
2020
Academic Article
GET IT
Times cited: 47 -
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.
JAMA oncology.
2019
Academic Article
GET IT
Times cited: 84 -
First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019
Academic Article
GET IT
Times cited: 178 -
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
The Journal of clinical investigation.
2019
Academic Article
GET IT
Times cited: 34 -
A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2019
Academic Article
GET IT
Times cited: 10 -
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 28 -
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.
Cancer.
2018
Academic Article
GET IT
Times cited: 42 -
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies.
Cancer chemotherapy and pharmacology.
2018
Academic Article
GET IT
Times cited: 35 -
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience.
BMC cancer.
2018
Academic Article
GET IT
Times cited: 75 -
Learning All That We Can From MyPathway.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Article
GET IT
Times cited: 1 -
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 86 -
Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 395 -
Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials.
Future oncology (London, England).
2018
Information Resource
GET IT
Times cited: 27 -
HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
Nature.
2018
Academic Article
GET IT
Times cited: 605 -
In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.
Radiology.
2018
Academic Article
GET IT
Times cited: 87 -
Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma.
Journal of the National Comprehensive Cancer Network : JNCCN.
2018
Academic Article
GET IT
Times cited: 16 -
Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation.
Oncotarget.
2017
Academic Article
GET IT
Times cited: 10 -
Reply to: "Adjuvant Medications that Improve Survival after Locoregional Therapy".
Journal of vascular and interventional radiology : JVIR.
2017
Article
GET IT
Times cited: 1 -
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Cancer.
2017
Academic Article
GET IT
Times cited: 33 -
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
2017
GET IT
Times cited: 23 -
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 80 -
Adjuvant Medications That Improve Survival after Locoregional Therapy.
Journal of vascular and interventional radiology : JVIR.
2017
Academic Article
GET IT
Times cited: 10 -
OncoKB: A Precision Oncology Knowledge Base.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 1754 -
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Nature medicine.
2017
Academic Article
GET IT
Times cited: 2416 -
A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.
Investigational new drugs.
2017
Academic Article
GET IT
Times cited: 12 -
Patient perspectives on ipilimumab across the melanoma treatment trajectory.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.
2017
Academic Article
GET IT
Times cited: 21 -
Hepatocellular carcinoma in patients with HIV.
Current opinion in HIV and AIDS.
2017
Information Resource
GET IT
Times cited: 12 -
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.
Journal of gastrointestinal oncology.
2016
Academic Article
GET IT
Times cited: 16 -
Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Chinese clinical oncology.
2016
Information Resource
GET IT
Times cited: 18 -
Advanced Hepatocellular Cancer: the Current State of Future Research.
Current treatment options in oncology.
2016
Information Resource
GET IT
Times cited: 37 -
Immunotherapy in hepatocellular carcinoma: Primed to make a difference?.
Cancer.
2015
Information Resource
GET IT
Times cited: 90 -
A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
The oncologist.
2015
Academic Article
GET IT
Times cited: 55 - Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?. Hepatobiliary surgery and nutrition. 2014 Academic Article GET IT
-
Treating advanced hepatocellular carcinoma: How to get out of first gear.
Cancer.
2014
Information Resource
GET IT
Times cited: 26 - From the liver to the foot: a case of systemic embolism and acrometastasis in hepatocellular carcinoma. Gastrointestinal cancer research : GCR. 2014 Academic Article GET IT
-
Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience.
Cancer.
2013
Academic Article
GET IT
Times cited: 164 -
Ipilimumab for patients with advanced mucosal melanoma.
The oncologist.
2013
Academic Article
GET IT
Times cited: 135 -
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.
Cancer journal (Sudbury, Mass.).
2012
Information Resource
GET IT
Times cited: 60 -
Vemurafenib sensitivity skin reaction after ipilimumab.
The New England journal of medicine.
2012
Article
GET IT
Times cited: 73